A Novel In Vitro Potency Assay Demonstrating the Anti-Fibrotic Mechanism of Action of CDCs in Deramiocel
Yujia Li, Justin B. Nice, Marya Kozinova , Stephanie Adachi, Linda Marban, Kristi Elliott and Minghao Sun
View ArticleTreatment with Deramiocel in DMD: Evidence of Long-Term Stabilization in Performance of Upper Limb Function Compared to Matched External Comparators (MDA 2025)
Craig M. McDonald, M.D., Chet Villa, M.D., Cuixia Tian, M.D., Alexander M. Zygmunt, M.D., Nicholas J. Ollberding, Ph.D., Kevin Berth, Upagna Desai, Zena Askerova Ph.D., Nathaniel J. Hogan, Ph.D., Kati S. Maharry, Ph.D., Mark S. Awadalla, Linda Marbán, Ph.D.
View ArticleMulti-modal benefits of deramiocel (CAP-1002) in late-stage patients with DMD: a new treatment approach to target skeletal and cardiac muscle pathogenesis (HOPE 2-OLE trial: 36-month data) (WMS 2024)
Craig M. McDonald, M.D., Chet Villa, M.D., Jonathan H. Soslow, M.D., Cuixia Tian, M.D., Alexander M. Zygmunt, M.D., Nicholas J. Ollberding, Ph.D., Kan N. Hor, M.D., Matthew M. Harmelink, M.D., Arun S. Varadhachary, M.D., Ph.D., Susan Apkon, M.D., Veena Ramanna, Upagna Desai, Nathaniel J. Hogan, Ph.D., Kati S. Maharry, Ph.D., Mark S. Awadalla, Linda Marbán, Ph.D.
View ArticleDeramiocel (CAP-1002) Demonstrates Disease Modification in Later-Stage DMD Patients 36-Month Safety and Efficacy Results from the HOPE-2 Open Label Extension (PPMD presentation)
View ArticleLong Term Safety and Efficacy of CAP-1002 in late-stage patients with DMD: A New Treatment Approach to Target Skeletal and Cardiac Muscle Pathogenesis (24-Month Data from HOPE-2-OLE Study)
Craig M. McDonald, MD, Suzanne Hendrix, PhD, Michelle Eagle, PhD, Matthew M. Harmelink, MD, Arun S. Varadhachary, MD, PhD, Cuixia Tian, MD, Susan Apkon, MD, Chet Villa, MD, Michael D. Taylor, MD, Kan N. Hor, MD, Mitchell Wassom, MS, Upagna Desai, Mark S. Awadalla, Linda Marbán, PhD
View ArticlePotency Assay Development for CAP-1002: An Allogeneic Cell Therapy in Phase 3 Clinical Trial for DMD
Minghao Sun, Kristi Elliott, Yujia Li, Lena Trinh, Firouz Mohsenian, Priya Mistry, Meena Murali, Stephanie Adachi, Esther Chin, Ben Canter, Arjang Salehi, Priyanka Ghorpade
View ArticleRepeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomized, double-blind, placebo-controlled, phase 2 trial
Craig M McDonald, Eduardo Marbán, Suzanne Hendrix, Nathaniel Hogan, Rachel Ruckdeschel Smith, Michelle Eagle, Richard S Finkel, Cuixia Tian, Joanne Janas, Matthew M Harmelink, Arun S Varadhachary, Michael D Taylor, Kan N Hor, Oscar H Mayer, Erik K Henricson, Pat Furlong, Deborah D Ascheim, Siegfried Rogy, Paula Williams, Linda Marbán, with the HOPE-2 Study Group
View ArticleIntracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial
Raj R Makkar, Dean J Kereiakes, Frank Aguirre, Glenn Kowalchuk, Tarun Chakravarty, Konstantinos Malliaras, Gary S Francis, Thomas J Povsic, Richard Schatz, Jay H Traverse, Janice M Pogoda, Rachel R Smith, Linda Marbán, Deborah D Ascheim, Mohammad R Ostovaneh, João A C Lima, Anthony DeMaria, Eduardo Marbán, Timothy D Henry
View ArticleAllogeneic cardiosphere derived cells (CAP 1002) in critically ill COVID 19 patients: compassionate use case series
Siddharth Singh, Tarun Chakravarty, Peter Chen, Akbarshakh Akhmerov, Jeremy Falk, Oren Friedman, Tanzira Zaman, Joseph E. Ebinger, Mitch Gheorghiu · Linda Marbán, Eduardo Marbán, Raj R. Makkar
View ArticleMicroRNA composition delineates cardiosphere-derived cell and mesenchymal stem cell extracellular vesicles
Ann-Sophie Walravens, Sasha Smolgovsky, Liang Li, Lauren Kelly, Travis Antes, Kiel Peck, Tanner Quon, Linda Marbán, Benjamin Berman, Luis R. Borlado, Geoffrey de Couto
View Article